Johnson & Johnson One Shot Covid-19 delayed vaccine

Johnson & Johnson’s (JNJ) – Get the report The Covid-19 monofuel vaccine is said to have exceeded its initial production schedule by two months and will not catch up until the end of April.

Citing people familiar with the matter, The New York Times reported that while Johnson & Johnson expects to release the results of the Covid-19 vaccine study in just two weeks, production is likely to face delays due to manufacturing delays that will prevent vaccine at the exit on the door and in his arms until April.

The delays come as the US continues to face record infections, hospitalizations and deaths from the new coronavirus, which has so far infected about 91.6 million people, resulting in more than 1.96 million deaths, according to Johns Hopkins University.

More than 4,300 people died of the disease on Tuesday, whereas the total number of deaths in the nation exceeded 380,000.

Johnson & Johnson Scientific Director Paul Stoffels told the Times that if the data is positive and the Food and Drug Administration approves the emergency vaccine, Johnson & Johnson could contribute to vaccination in the United States sometime in March.

However, the apparent delays in Johnson & Johnson’s production capabilities could still hamper efforts to launch the vaccine and take it in its arms. Federal officials were told that the company had dropped by up to two months from the initial production schedule and would not catch up until the end of April, when it was supposed to have delivered more than 60 million doses.

.Source

Share this:

Related